Video

ASCRS Live: STAAR Surgical looks toward the future of eye care

Warren Foust, chief operating officer of STAAR Surgical, discussed the company and looked toward the future at the 2023 ASCRS annual meeting in San Diego.

Warren Foust, chief operating officer of STAAR Surgical, discussed the company and looked toward the future at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Warren Foust:

I'm Warren Foust. I'm the chief operating officer of STAAR Surgical. San Diego has been an amazing meeting. We're coming down to the end but we've had such a wonderful time here at STAAR Surgical.

The EVO ICL continues to gain in popularity—a wonderful showing at the Eyecelerator meeting, which we were grateful to be part of, and also [an] amazing time with so much traffic at our booth. I'm grateful to Ophthalmology Times for bringing us to this forum.

I just want to say how excited I am to be part of STAAR Surgical and also want to say how exciting of a time it is for refractive surgery. STAAR [Surgical] is the only company in the space that is truly investing in our customers' ability to grow the refractive practice. Patients around the world—2 million strong—have given us amazing reaction to the implantation of the EVO ICL, 99.4% would say they're satisfied. In a recent study of over 900 surgeons, we got similar levels of satisfaction. So really excited about that. What we've learned through that process is that a happy EVO ICL patient grows a refractive practice.

I wish each one of you good luck as you start to engage with us. Please look for us at the booth the rest of the time. Please spend time with our teams. We're happy to market with you. We're happy to be part of the refractive market with you. Thank you.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.